Immune System

Angioedema: histaminergic vs bradykinin-mediated

Clinical Overview and When to Suspect Angioedema

— Histaminergic (mast-cell mediated): IgE allergic, NSAID pseudo-allergic, idiopathic; responds to epinephrine, antihistamines, glucocorticoids; often with urticaria, pruritus, flushing, bronchospasm, hypotension.

— Bradykinin-mediated: ACE inhibitor–induced, hereditary angioedema (HAE types I/II/III), acquired C1-INH deficiency; no urticaria, no pruritus, slower onset (hours), prolonged course (2–5 days), unresponsive to epinephrine/antihistamines/steroids.

— Acute lip/tongue/face swelling, voice change, dysphagia, drooling, stridor.

— Recurrent unexplained abdominal pain with vomiting in a patient on ACEi or with family history (HAE bowel attacks).

— Tongue swelling in a Black patient on lisinopril → ACEi-induced is 4–5× more common in Black patients.

Angioedema = self-limited, asymmetric, non-pitting swelling of deep dermis, subcutaneous tissue, or submucosa, often involving lips, tongue, periorbital area, larynx, genitalia, or bowel wall.

Two pathophysiologic buckets drive ED decision-making:

When to suspect angioedema in the ED:

Mortality is almost entirely from upper airway obstruction; the clinician's first job is airway disposition, the second is mechanism identification.

Board pearl: Urticaria + pruritus + rapid onset (minutes) = histaminergic. Isolated, non-pruritic, non-urticarial swelling that creeps up over hours on a patient taking lisinopril or with a positive family history = bradykinin-mediated until proven otherwise.

Step 3 management trigger: Any laryngeal involvement (hoarseness, stridor, tongue protrusion past teeth, floor-of-mouth swelling) mandates immediate airway team mobilization and ICU disposition regardless of mechanism — empiric epinephrine IM is still given because misclassification risk is high and harm is low.

Step 3 vignettes reward you for recognizing that bradykinin-mediated angioedema is frequently misdiagnosed and re-exposed, leading to recurrent ED visits — pharmacy reconciliation and EHR allergy listing are tested patient-safety endpoints.

Presentation Patterns and Key History

— Onset minutes after trigger (food, drug, latex, sting, contrast, NSAID).

— Urticaria (wheals), pruritus, flushing, wheeze, GI cramping, hypotension = part of the anaphylaxis spectrum.

— Resolves within 24–48 hours with treatment.

— Can occur any time — days to years after starting the drug (median ~months but classic boards trap: "on lisinopril for 6 years").

— Predilection for tongue, lips, face; rarely involves bowel.

— No urticaria, no itch.

— Risk factors: Black race, smoking, female, age >65, prior ACEi angioedema, concurrent mTOR inhibitor or DPP-4 inhibitor, seasonal allergies.

— Onset usually childhood/adolescence; autosomal dominant; 25% are de novo mutations so absent family history does not exclude.

— Attacks last 2–5 days, often preceded by tingling or erythema marginatum (serpiginous non-pruritic rash).

— Triggers: dental work, trauma, estrogen (OCPs, pregnancy), ACEi, stress, infection.

— Recurrent abdominal pain with vomiting/diarrhea from intestinal wall edema → frequently misdiagnosed as appendicitis or SBO; CT shows bowel wall thickening with ascites.

— Adult onset >40, associated with lymphoproliferative disorders (MGUS, B-cell lymphoma) or autoimmune disease.

— Full med rec including ARBs, NSAIDs, sacubitril/valsartan, gliptins, tPA, estrogens.

— Prior episodes, family history, dental/surgical triggers, food/insect exposure.

— Time course (minutes vs hours), pruritus, urticaria, GI symptoms.

Histaminergic presentation:

ACE inhibitor–induced angioedema:

Hereditary angioedema (HAE):

Acquired C1-INH deficiency:

Key history checklist:

Key distinction: Speed and itch are your two best bedside discriminators — fast + itchy = histamine; slow + non-itchy = bradykinin. Get this right before you pick the drug.

Board pearl: ARBs cause angioedema at lower rates than ACEi but can cross-react; switching to an ARB requires shared decision-making and 4-week washout with avoidance if prior episode was severe/laryngeal.

Physical Exam Findings and Airway Assessment

— Inspect lips, tongue (size, protrusion past teeth), floor of mouth, uvula, soft palate, posterior pharynx.

— Listen for voice change, hoarseness, muffled "hot potato" voice, stridor — these signal supraglottic involvement.

— Assess drooling, dysphagia, tripod posture, accessory muscle use, SpO₂.

— Stage I: facial/lip swelling only — observation.

— Stage II: soft palate involvement — monitored bed.

— Stage III: tongue swelling — ICU, prepare difficult airway.

— Stage IV: laryngeal edema — immediate airway intervention.

— Urticaria/wheals → histaminergic.

— Erythema marginatum (non-raised serpiginous rash on trunk/extremities) → HAE prodrome.

— No skin findings + isolated submucosal swelling → bradykinin.

— Diffuse tenderness without peritoneal signs in a patient with HAE = bowel wall angioedema; CT confirms, avoid unnecessary laparotomy.

— Hypotension, tachycardia, bronchospasm = anaphylaxis → IM epinephrine 0.3–0.5 mg lateral thigh.

— Bradykinin-mediated attacks rarely cause shock; if hypotensive, reconsider diagnosis.

Targeted airway exam — the highest-yield action:

Ishoo staging for ACEi angioedema (high-yield framework):

Skin exam:

Abdominal exam:

Hemodynamics:

Fiberoptic nasopharyngoscopy at bedside is the gold standard for assessing supraglottic/laryngeal involvement when external exam is equivocal — Step 3 favors early ENT/anesthesia consultation for borderline cases.

CCS pearl: On a CCS case, the order set for suspected angioedema with any voice change should include: continuous pulse oximetry, cardiac monitor, two large-bore IVs, ENT and anesthesia consult, head-of-bed elevation, NPO, and bedside airway cart with video laryngoscope + cricothyrotomy kit before you choose pharmacotherapy. Reassess airway every 15–30 minutes; document each reassessment because progression can be rapid and silent.

Board pearl: Tongue protruding past the teeth, inability to handle secretions, or stridor = secure airway now, do not wait for medications to work.

Diagnostic Workup — Initial Labs and Bedside Studies

— CBC, BMP, LFTs — baseline organ function, eosinophilia may hint at parasitic or hypereosinophilic syndromes.

— Tryptase: drawn within 1–2 hours of symptom onset, repeat at 24 hours for baseline.

– Elevated acute tryptase (>11.4 ng/mL or >20% + 2 above baseline) supports mast cell activation (anaphylaxis/histaminergic).

– Normal tryptase is expected in bradykinin-mediated angioedema.

— Consider total IgE and specific IgE if allergen identified.

— Soft-tissue neck CT or lateral neck radiograph only if airway is secure and diagnosis unclear — do not delay airway management for imaging.

— Abdominal CT for suspected HAE bowel attack: bowel wall thickening, mesenteric edema, ascites, "stacked coins" appearance, often jejunum/ileum; resolves with attack.

Angioedema is fundamentally a clinical diagnosis; labs serve to support mechanism classification, identify triggers, and rule out mimics.

Initial ED workup:

Imaging:

ECG and continuous monitoring if anaphylaxis features, advanced age, or epinephrine use — watch for ischemia, arrhythmia.

Bedside laryngoscopy by ENT or anesthesia for any voice change, dysphagia, or stridor.

Pregnancy test in reproductive-age females — affects medication choice (icatibant pregnancy category, estrogen consideration).

Step 3 management: When the clinical picture is ambiguous (e.g., patient on lisinopril with mild urticaria), treat both pathways empirically: IM epinephrine + antihistamines + steroids AND stop the ACEi; obtain tryptase and C4 to sort retrospectively. Misclassification toward "just allergic" misses ACEi etiology and risks re-exposure.

Key distinction: Tryptase distinguishes mechanism only if drawn in the right window (1–2 hours peak, normalizes by 4–6 hours). A normal tryptase drawn 6 hours after onset does not rule out anaphylaxis.

Board pearl: Eosinophilia + recurrent angioedema + fever + weight gain = Gleich syndrome (episodic angioedema with eosinophilia) — rare but a favorite distractor.

Diagnostic Workup — Confirmatory and Outpatient Studies

— C4 level: screening test. Low C4 during and between attacks suggests HAE type I/II or acquired C1-INH deficiency.

– C4 is the single best initial screen — sensitivity ~80–90% during attacks, near 100% in HAE.

— C1 inhibitor level (quantitative): low in HAE type I (85% of cases).

— C1 inhibitor function: low in HAE type II (functional defect with normal/high antigenic level, ~15%).

— C1q level: low in acquired C1-INH deficiency (autoantibody or consumption from lymphoproliferative disease); normal in hereditary — this is a classic exam point.

— Estrogen-dependent, predominantly female, normal C4/C1-INH/C1q.

— Genetic testing: F12, PLG, ANGPT1, KNG1 mutations.

— Skin prick testing and specific IgE for suspected food, venom, drug allergens — done 4–6 weeks after the episode (refractory period).

— Drug challenge under allergist supervision when indicated.

— SPEP/UPEP, free light chains, flow cytometry, age-appropriate cancer screening — search for MGUS, lymphoma, autoimmune disease.

— All ACEi/ARB-induced cases get lifelong ACEi avoidance flagged in the chart and pharmacy system.

— HAE I: ↓C4, ↓C1-INH level, ↓function, normal C1q

— HAE II: ↓C4, normal/↑C1-INH level, ↓function, normal C1q

— Acquired: ↓C4, ↓C1-INH, ↓function, ↓C1q

— ACEi-induced: all normal

Confirmatory workup is typically deferred to outpatient allergy/immunology but Step 3 expects you to order the right labs and interpret them.

Complement studies for suspected bradykinin angioedema:

HAE with normal C1-INH (formerly type III):

Allergy workup for histaminergic disease:

Workup for acquired C1-INH deficiency:

Discontinue and document:

Board pearl: Memorize this table:

Step 3 management: Refer all confirmed or suspected HAE patients to allergy/immunology for long-term prophylaxis planning, attack plan, and family screening — first-degree relatives need C4 and C1-INH testing.

Risk Stratification and First-Line Management Logic

— High risk (secure airway now): stridor, hypoxia, tongue protrusion, drooling, respiratory distress, rapid progression.

— Moderate risk (ICU monitoring, awake fiberoptic intubation readiness): voice change, dysphagia, floor-of-mouth or posterior tongue/uvula edema.

— Low risk (monitored bed/observation): lip-only or facial swelling, no oropharyngeal involvement, stable for >4 hours.

— Histaminergic/anaphylaxis: IM epinephrine 0.3–0.5 mg q5–15 min, H1 antihistamine (cetirizine or diphenhydramine), H2 blocker (famotidine), glucocorticoid (methylprednisolone 125 mg IV), IV fluids.

— Bradykinin-mediated (HAE attack): C1-INH concentrate (Berinert, Cinryze 20 U/kg IV), icatibant (B2 receptor antagonist, 30 mg SC), or ecallantide (kallikrein inhibitor, 30 mg SC, US only, monitor for anaphylaxis). Fresh frozen plasma is a second-line option when targeted agents unavailable.

— ACEi-induced: Stop the drug. Targeted bradykinin agents (icatibant, C1-INH) may shorten attacks but evidence is mixed; still commonly given for moderate–severe cases. Empiric epinephrine/antihistamines/steroids are reasonable if mechanism is unclear.

Management priorities in order: (1) airway, (2) mechanism-directed pharmacotherapy, (3) trigger removal, (4) disposition.

Airway risk stratification:

Mechanism-directed first line:

Trigger removal: discontinue offending drug, remove stinger, decontaminate allergen exposure.

Step 3 management: A patient with isolated tongue swelling on lisinopril without urticaria — stop the ACEi, admit for airway monitoring (typically 24 hours), give empiric epinephrine/antihistamines/steroids if any doubt about mechanism, and document lifelong ACEi allergy. ARBs can be cautiously considered later but not in the acute setting.

CCS pearl: Advance the clock in small increments (15–30 minutes) when airway is threatened. Reassess airway, vitals, and response after every intervention; do not jump 2 hours forward and miss decompensation.

Board pearl: Antihistamines and steroids do not work in pure bradykinin-mediated angioedema, but you still often give them empirically because misclassification carries higher risk than the cost of unnecessary drugs.

Pharmacotherapy — First-Line Drug Regimens

— Epinephrine 0.3–0.5 mg IM (1 mg/mL concentration), anterolateral thigh, repeat q5–15 min as needed. IV epinephrine infusion (1–10 mcg/min) for refractory shock — never bolus IV epi outside of arrest.

— H1 antihistamine: cetirizine 10 mg IV/PO (preferred, less sedating) or diphenhydramine 25–50 mg IV.

— H2 antihistamine: famotidine 20 mg IV.

— Glucocorticoid: methylprednisolone 1–2 mg/kg IV or prednisone 1 mg/kg PO — onset 4–6 hours, intended to blunt biphasic reactions.

— Albuterol nebulizer for bronchospasm.

— IV crystalloid bolus 1–2 L for hypotension.

— C1-esterase inhibitor concentrate (plasma-derived Berinert, recombinant Ruconest) 20 U/kg IV — onset ~30 min.

— Icatibant 30 mg SC abdomen — selective bradykinin B2 receptor antagonist, onset ~30–60 min, may repeat q6h up to 3 doses/24 h.

— Ecallantide 30 mg SC (three 10 mg injections) — kallikrein inhibitor; black-box warning for anaphylaxis, administer in healthcare setting only.

— FFP 2 units IV if no targeted therapy available (contains C1-INH but also substrates; rarely worsens attack).

— Stop ACEi permanently.

— Targeted bradykinin agents (icatibant, C1-INH) are commonly used for moderate–severe cases though RCT evidence is mixed.

— Supportive airway management remains the cornerstone.

— Epinephrine 0.01 mg/kg IM (max 0.3 mg).

— Icatibant approved age ≥2 in US; C1-INH approved in pediatrics.

Anaphylaxis/histaminergic angioedema (the AHA/AAAAI bundle):

HAE acute attack — choose ONE first-line agent:

ACEi-induced angioedema:

Pediatric dosing:

Board pearl: Beta-blocker–treated patients may have refractory anaphylaxis unresponsive to epinephrine — give glucagon 1–5 mg IV to bypass beta-receptor blockade.

Step 3 management: Discharge prescription for every anaphylaxis patient includes two epinephrine auto-injectors, allergist referral within 1–4 weeks, and a written anaphylaxis action plan. Confirm the patient can demonstrate auto-injector technique before leaving.

Airway Procedures and Advanced Management

— Progressive symptoms despite therapy, stridor, hypoxia, tongue protrusion, inability to phonate or handle secretions.

— Err early — angioedema airways become impossible airways quickly; what looks like a "watch" patient at hour 1 may be a surgical airway at hour 3.

— Awake fiberoptic nasotracheal intubation by most experienced operator in OR or controlled ED setting.

— Topical anesthesia (lidocaine), minimal sedation, preserve spontaneous ventilation.

— Have double setup: surgical airway (cricothyrotomy kit or tracheostomy) prepped and surgeon scrubbed.

— Blind nasal intubation (trauma can worsen edema).

— Heavy sedation/paralysis before securing airway in a difficult anatomy.

— Repeated laryngoscopy attempts — each attempt worsens edema.

— Indicated for "can't intubate, can't oxygenate"; submental and tongue swelling may distort landmarks — identify cricothyroid membrane early when possible.

— Resolution of supraglottic edema confirmed by direct laryngoscopy or cuff-leak test, typically 24–72 hours.

— Consider steroid coverage peri-extubation in select cases.

— First-line long-term prophylaxis: subcutaneous C1-INH (Haegarda) every 3–4 days, lanadelumab (anti-kallikrein mAb) SC q2–4 weeks, or berotralstat (oral kallikrein inhibitor) daily.

— Short-term prophylaxis before dental/surgical procedures: C1-INH 1 hour pre-procedure; alternatives include attenuated androgens (danazol) or tranexamic acid in resource-limited settings.

Airway management is the procedural cornerstone — bradykinin angioedema mortality is driven by failed/delayed airway, not by the swelling itself.

Threshold to intubate:

Preferred technique:

Avoid:

Cricothyrotomy/surgical airway:

Extubation criteria:

Long-term HAE prophylaxis (outpatient, but board-tested):

CCS pearl: For any patient admitted with oropharyngeal angioedema, document airway reassessment q1–2 h, keep NPO, head of bed elevated, and have an "airway plan" written in the chart specifying primary technique, backup, and surgical airway operator.

Board pearl: Attenuated androgens (danazol, stanozolol) are effective HAE prophylaxis but contraindicated in pregnancy and children — switch to C1-INH or lanadelumab.

Special Populations — Elderly and Renal/Hepatic Impairment

— Higher prevalence of ACEi/ARB use → disproportionate share of ACEi angioedema in the ED.

— Polypharmacy increases risk: DPP-4 inhibitors (sitagliptin, saxagliptin), neprilysin inhibitors (sacubitril/valsartan), mTOR inhibitors (sirolimus, everolimus), and tPA all potentiate bradykinin and can precipitate or worsen attacks.

— Reduced physiologic reserve → lower threshold for ICU admission and earlier airway intervention.

— Epinephrine cautions: known CAD, uncontrolled HTN, tachyarrhythmias — but never withhold epinephrine in true anaphylaxis; consider lower-dose initial IM (0.3 mg) with continuous cardiac monitoring.

— Icatibant: no dose adjustment needed (metabolized by proteases, not renally cleared).

— Ecallantide: no renal adjustment.

— C1-INH concentrate: no renal adjustment.

— Cetirizine: reduce dose in CrCl <30.

— Famotidine: reduce in CKD stage 3+.

— Androgens (danazol) hepatotoxic — avoid in significant liver disease; monitor LFTs and lipids if used.

— Tranexamic acid relatively safe.

— Sacubitril/valsartan combines neprilysin inhibition with ARB → contraindicated within 36 hours of an ACEi and contraindicated in patients with prior angioedema.

— Patients with prior ACEi angioedema needing RAAS blockade: use ARB with caution and shared decision-making; sacubitril/valsartan generally avoided.

Elderly patients:

Renal impairment:

Hepatic impairment:

Heart failure considerations:

Step 3 management: A 78-year-old on lisinopril, sacubitril/valsartan switch is contemplated — recognize that prior ACEi angioedema is a contraindication to sacubitril/valsartan; alternative HF regimen (e.g., hydralazine/nitrate + beta-blocker + MRA + SGLT2 inhibitor) is appropriate.

Board pearl: When an elderly patient presents with recurrent unexplained abdominal pain and low C4, think acquired C1-INH deficiency — order SPEP and consider hematology referral to evaluate for occult lymphoproliferative disorder before labeling as HAE.

Special Populations — Pregnancy and Pediatrics

— HAE attacks can increase, decrease, or stay the same during pregnancy; estrogen-dependent HAE (normal C1-INH type) often worsens.

— First-line acute therapy in pregnancy: plasma-derived C1-INH concentrate (Berinert) — extensive safety data, preferred agent.

— Icatibant — limited human data, used when C1-INH unavailable; case series suggest safety.

— Ecallantide — limited data, generally avoided.

— Contraindicated in pregnancy: attenuated androgens (danazol — virilization), tranexamic acid is relatively safe (used for postpartum hemorrhage) but generally avoided as prophylaxis unless C1-INH unavailable.

— ACE inhibitors and ARBs are contraindicated in all trimesters (renal dysgenesis, oligohydramnios) — and obviously avoided in any patient with prior angioedema.

— Delivery: vaginal delivery preferred; pre-delivery C1-INH prophylaxis for high-risk patients.

— HAE often presents in childhood/adolescence with abdominal pain or peripheral swelling; laryngeal attacks rare before puberty but lethal when they occur.

— Pediatric dosing:

– Epinephrine 0.01 mg/kg IM (max 0.3 mg <30 kg, 0.5 mg ≥30 kg).

– C1-INH 20 U/kg IV — approved all ages.

– Icatibant approved ≥2 years (US).

– Lanadelumab approved ≥2 years for prophylaxis.

— Avoid androgens in children — growth/sexual development effects.

— First-degree relatives of HAE patients should be screened (C4 + C1-INH level and function) regardless of symptoms; presymptomatic diagnosis allows trigger avoidance and pre-procedural prophylaxis.

Pregnancy:

Lactation: C1-INH and icatibant considered compatible; minimal transfer.

Pediatrics:

Step 3 management: A 14-year-old with recurrent abdominal pain and a father with HAE — order C4 first; if low, follow with C1-INH level and function. Refer to pediatric allergy/immunology and counsel family on attack action plan and ER card.

Board pearl: OCPs, postmenopausal estrogen, and pregnancy are classic HAE-attack triggers — switch to progestin-only contraception in HAE.

Complications and Adverse Outcomes

— Leading cause of death in HAE and ACEi angioedema (HAE historic mortality ~30% before targeted therapy; now <5% with modern agents and recognition).

— Pre-hospital deaths occur from delayed presentation or rapid laryngeal swelling.

— Cardiovascular collapse, biphasic reactions in up to 20% within 1–72 hours after initial recovery → observation 4–6 hours minimum for mild reactions; longer for severe.

— Mimic acute abdomen → unnecessary laparoscopy/laparotomy if HAE not recognized.

— Hypovolemia from third-spacing into bowel wall → hypotension, AKI.

— Failed intubation attempts worsen edema and cause hemorrhage.

— Epinephrine in elderly/CAD: tachyarrhythmias, MI, hypertensive crisis — but withholding epi causes more deaths than it prevents.

— Steroid-related hyperglycemia, mood, infection.

— Long-term androgen prophylaxis: hepatic adenoma/HCC, dyslipidemia, virilization, depression — requires q6-month LFTs, lipids, AFP, and liver ultrasound.

— Up to 50% of ACEi angioedema cases are missed initially and re-exposed; subsequent attacks can be more severe.

— Documentation in EHR allergy field is a Step 3 patient-safety priority.

— Frequent ED visits, school/work absenteeism, anxiety, PTSD — HAE patients benefit from advocacy organizations (HAEA, USHAEA).

Asphyxiation:

Hypoxic-ischemic brain injury from delayed airway management — a tested patient-safety endpoint.

Anaphylactic shock:

Bowel attacks (HAE):

Iatrogenic complications:

Recurrence and re-exposure:

Psychosocial:

Board pearl: Biphasic anaphylaxis occurs in 5–20% — observe for at least 4 hours after symptom resolution; longer (8–24 h) if severe, required >1 epi dose, or beta-blocker therapy.

Step 3 management: Every patient with anaphylaxis or ACEi/HAE angioedema discharged from the ED needs: documented allergy/contraindication in chart, written action plan, two epinephrine auto-injectors (for histaminergic), allergist or immunologist follow-up, and patient education on trigger avoidance — these are tested as bundled discharge criteria.

When to Escalate Care — ICU, Consults, Inpatient Triage

— Intubated or imminent airway compromise.

— Stage III–IV Ishoo (tongue/laryngeal involvement).

— Refractory anaphylaxis requiring epinephrine infusion or vasopressors.

— Severe biphasic reaction risk: prior near-fatal episode, beta-blocker therapy, ACEi laryngeal involvement.

— Stage II Ishoo (soft palate/uvula involvement, no tongue/laryngeal).

— Anaphylaxis requiring multiple epi doses but stable on discharge from ED.

— Patients with significant comorbidities (CAD, advanced age) post-epi.

— Persistent moderate facial/lip swelling without airway threat.

— HAE bowel attack requiring IV fluids and analgesia.

— Stage I Ishoo (lip/face only), stable >4–6 hours, no progression, no laryngeal symptoms, reliable follow-up, auto-injectors prescribed.

— ENT and Anesthesia: any voice change, dysphagia, oropharyngeal involvement — for nasopharyngoscopy and airway planning.

— Allergy/Immunology: all suspected HAE, recurrent histaminergic, drug allergy workup, long-term prophylaxis planning.

— Hematology/Oncology: acquired C1-INH deficiency workup (lymphoproliferative disease).

— Pharmacy: medication reconciliation, EHR allergy entry, alternative regimen planning.

— Cardiology: if ACEi indication was HFrEF/CAD — plan alternative RAAS strategy.

ICU admission criteria:

Step-down/telemetry or monitored bed:

General floor admission:

Discharge from ED (safe disposition):

Consults to obtain:

CCS pearl: When a CCS case has angioedema with tongue swelling, advance time only in 15-minute increments, write "consult ENT," "consult Anesthesia," "ICU admission," "stop lisinopril (permanent)," and order continuous pulse oximetry and cardiac monitoring before advancing further. Failing to obtain airway consults is a flagged management error.

Board pearl: Recurrent angioedema attacks in a patient with no family history, adult onset, low C4 AND low C1q → mandatory hematology referral; the lymphoma may not yet be clinically apparent.

Step 3 management: Document the rationale for airway disposition explicitly; "patient observed, airway stable" without serial reassessments is a common malpractice/board trap.

Key Differentials — Same-Category (Other Swelling Syndromes)

— Periorbital or facial swelling with erythema, vesicles, weeping — distinguish by skin appearance.

— Treat with topical/oral steroids; epinephrine not needed.

— Erythema, warmth, tenderness, fever, leukocytosis, unilateral, sharp borders (erysipelas).

— Angioedema is non-erythematous, non-tender, asymmetric but not following lymphatic patterns.

— Facial/neck/upper extremity edema, plethora, distended neck veins, dyspnea — subacute, often malignancy-related.

— Imaging (CT chest) confirms.

— Generalized non-pitting edema, periorbital puffiness, macroglossia — chronic, with hypothyroid features.

— Periorbital edema worse in morning, proteinuria, hypoalbuminemia — chronic onset.

— Cyclic angioedema, urticaria, fever, weight gain, marked eosinophilia (>5000/μL), elevated IgM.

— Recurrent flushing, urticaria, angioedema, GI symptoms, hypotension; elevated baseline tryptase >20 ng/mL; KIT D816V mutation.

— Diagnosis of exclusion after ruling out hereditary, acquired, drug-induced, allergic causes.

— Often histaminergic — empirical trial of high-dose H1 antihistamines (up to 4× standard dose).

— Estrogen-dependent, female predominant, normal complement studies, F12/PLG/ANGPT1/KNG1 mutations.

Allergic contact dermatitis with facial edema:

Cellulitis/erysipelas of the face:

Superior vena cava syndrome:

Hypothyroidism (myxedema):

Acute glomerulonephritis/nephrotic syndrome:

Episodic angioedema with eosinophilia (Gleich syndrome):

Mast cell activation syndrome / systemic mastocytosis:

Idiopathic angioedema:

Hereditary angioedema with normal C1-INH (HAE-nl-C1INH, formerly type III):

Key distinction: True angioedema is non-pitting, asymmetric, and involves submucosa/deep dermis. Pitting edema, bilateral and dependent, suggests systemic causes (CHF, renal, hepatic) — not angioedema.

Board pearl: Recurrent angioedema with normal complement studies in a young woman started on OCPs → HAE with normal C1-INH — switch to progestin-only contraception, refer to immunology, consider F12 gene testing.

Key Differentials — Other-Category Causes

— Urticaria, bronchospasm, hypotension, GI symptoms — same treatment but presentation differs.

— Ludwig angina: bilateral submandibular cellulitis, woody floor of mouth, dental source, fever — needs IV antibiotics + drainage.

— Epiglottitis: fever, drooling, tripod posture, "thumb sign" on lateral neck X-ray; less common in adults post-Hib vaccine but emerging in adults — keep in differential for stridor without external swelling.

— Retropharyngeal/peritonsillar abscess: sore throat, trismus, muffled voice, deviated uvula (peritonsillar), neck pain (retropharyngeal).

— Diphtheria: rare in US, pseudomembrane, low immunization status.

— Direct mast cell degranulation, not IgE-mediated; treat as histaminergic anaphylaxis.

— Sacubitril/valsartan, DPP-4 inhibitors (gliptins), tPA, mTOR inhibitors — recognize and discontinue.

— Histamine-rich spoiled fish (tuna, mahi-mahi); flushing, urticaria, GI symptoms within 1 hour of ingestion; responds to antihistamines; mimics IgE allergy but is a toxin.

— Physical urticarias; recurrent, trigger-specific.

Anaphylaxis without prominent angioedema:

Acute infectious processes mimicking airway swelling:

Foreign body aspiration: sudden onset, localized stridor, no swelling — bronchoscopy diagnostic and therapeutic.

Anaphylactoid reactions to contrast or NSAIDs:

Drug-induced (non-ACEi) bradykinin-mediated angioedema:

Scombroid poisoning:

Vibratory or cold/cholinergic urticaria with angioedema:

Capillary leak syndrome (Clarkson): rare; recurrent hypotension, hemoconcentration, hypoalbuminemia, generalized edema — not true angioedema but mimics.

Step 3 management: A patient with sore throat, drooling, fever, and stridor without facial/lip swelling is not angioedema — think Ludwig angina or epiglottitis; order lateral neck X-ray or CT (if stable), broad-spectrum antibiotics, and ENT/anesthesia for airway management.

Board pearl: Tongue-only swelling in a patient just started on sacubitril/valsartan — recognize this as neprilysin inhibitor-induced bradykinin angioedema; switch to a different HF regimen permanently.

Secondary Prevention and Long-Term Plan

— Lifelong avoidance of all ACE inhibitors — document in EHR allergy field, counsel patient verbally and in writing, provide medical alert bracelet recommendation.

— ARB risk of cross-reactivity is ~2–10%; can be considered after 4–6 week washout with shared decision-making, but avoid in laryngeal/severe cases.

— Sacubitril/valsartan contraindicated if prior ACEi angioedema.

— Alternative antihypertensives: thiazide, CCB, beta-blocker (if indicated), spironolactone.

— Alternative HF regimens: hydralazine/nitrate, beta-blocker, MRA, SGLT2 inhibitor.

— First-line: SC C1-INH (Haegarda) q3–4 days, lanadelumab (anti-kallikrein mAb) SC q2–4 weeks, berotralstat (oral kallikrein inhibitor) daily.

— Second-line: attenuated androgens (danazol) — avoid in pregnancy, children, liver disease; monitor LFTs, lipids, AFP, hepatic US q6 months.

— Tranexamic acid: occasional use in pediatrics or when first-line unavailable.

— Patients trained to self-administer SC icatibant or IV C1-INH for attacks; reduces ED utilization and improves outcomes.

— Two epinephrine auto-injectors prescribed at discharge; demonstrate technique.

— Allergist referral for skin testing, specific IgE, drug/food challenge as indicated.

— Trigger avoidance plan, medical alert bracelet.

— Consider venom immunotherapy for confirmed insect sting anaphylaxis (highly effective).

— Daily H1 antihistamines at up to 4× standard dose (e.g., cetirizine 40 mg/day) per guidelines; omalizumab as add-on for refractory cases.

— Written action plan, attack diary, ER card, contact information for specialist.

— Family screening for HAE.

ACEi-induced angioedema:

HAE long-term prophylaxis (indicated if frequent/severe attacks):

HAE on-demand therapy at home:

Anaphylaxis/histaminergic:

Idiopathic angioedema:

Patient education:

Step 3 management: Document every angioedema discharge with: confirmed mechanism (or working diagnosis), allergy/contraindication entered in EHR, prescriptions sent, follow-up scheduled, action plan provided, and demonstration of injector technique.

Board pearl: USHAEA and HAEA patient advocacy organizations provide free attack action plan templates and ER cards — recommending these is a tested patient-engagement step.

Follow-Up, Monitoring, and Counseling

— Primary care: within 1–2 weeks to review event, confirm medication changes, reinforce trigger avoidance.

— Allergy/Immunology: within 4 weeks for all suspected HAE, recurrent histaminergic, drug allergy, or unclear mechanism cases.

— Hematology: if acquired C1-INH suspected (low C1q).

— Attenuated androgens (danazol): LFTs, lipid panel, CBC, AFP every 6 months; liver ultrasound annually to screen for hepatic adenoma/HCC.

— Lanadelumab/berotralstat/C1-INH: monitor attack frequency, severity, dosing intervals; minimal lab monitoring required.

— Chronic antihistamines: monitor for sedation, anticholinergic effects in elderly.

— Long-term steroids (avoid): if used, monitor BP, glucose, bone density, screen for infections.

— Patient-maintained attack diary (date, location, trigger, severity, treatment, response) — informs prophylaxis decisions.

— Quality of life measures (AE-QoL, HAE-QoL) used in clinic.

— Recognize early symptoms (prodrome, tingling, erythema marginatum).

— When to use rescue therapy vs go to ER.

— Trigger avoidance: ACEi, estrogens (HAE), known allergens, trauma minimization (mouth guards, dental prophylaxis).

— Pre-procedural prophylaxis for HAE before dental work or surgery (C1-INH 1 hour pre-procedure).

— Pregnancy planning for HAE: switch to plasma-derived C1-INH for both acute and prophylactic use.

— Routine; no specific contraindications.

— Annual influenza, COVID, age-appropriate immunizations encouraged.

— All first-degree relatives — C4 + C1-INH level and function; consider genetic testing for HAE-nl-C1INH.

Post-ED follow-up cadence:

Monitoring parameters by therapy:

Attack tracking:

Counseling priorities:

Vaccination:

Family screening for HAE:

Step 3 management: When the patient asks "Can I ever take an ACE inhibitor again?" — the answer is no, lifelong avoidance for any prior ACEi-induced angioedema, regardless of severity, because subsequent attacks can be fatal even if prior episode was mild.

Board pearl: A patient on long-term danazol with new RUQ pain and elevated AFP → suspect hepatic adenoma or HCC; get liver imaging urgently.

Ethical, Legal, and Patient Safety Considerations

— Failure to flag ACEi-induced angioedema in the EHR is one of the most common preventable causes of recurrence and a frequent malpractice claim.

— Document with mechanism (e.g., "ACEi-induced angioedema, bradykinin-mediated"), severity, date, and contraindicated class (all ACEi, sacubitril/valsartan).

— Class-level alerts must be active so re-prescription triggers a hard stop.

— At discharge, ensure ACEi removed from active medication list, pharmacy is notified, and outpatient prescriber is informed.

— Med reconciliation at every transition (ED→floor, floor→home, primary→specialist) is a Joint Commission patient safety priority.

— Hand-off communication should include "this patient cannot ever receive ACE inhibitors."

— ARB trial after prior ACEi angioedema: explicit shared decision-making, document benefit/risk discussion (2–10% cross-reactivity), avoid if prior laryngeal involvement.

— Pediatric HAE prophylaxis with off-label agents: parental consent + assent from child where appropriate.

— Difficult airway algorithm requires the most experienced operator available — calling for backup is not optional.

— Documented airway plan including primary, backup, and surgical airway provider.

— Drug-induced angioedema can be reported to FDA MedWatch (voluntary but encouraged) — contributes to post-marketing surveillance.

— Black patients have 4–5× higher ACEi angioedema risk — Step 3 expects you to integrate this into prescribing decisions, particularly when ARBs or thiazides may be more appropriate first-line choices for hypertension in Black patients per JNC/ACC/AHA recommendations.

— A patient declining hospital admission for stable lip-only ACEi angioedema may leave AMA if competent — document capacity assessment, risks, and 24-hour return precautions; provide written instructions.

EHR allergy documentation:

Transition-of-care risks:

Informed consent edge cases:

Airway management ethics:

Mandatory reporting:

Health equity:

Patient autonomy:

Step 3 management: When transferring a patient with HAE to another facility for higher-level airway care, send the complete medication list, recent C1-INH/lanadelumab dosing, and attack history, and call report directly to the receiving physician — handoff failures cause preventable deaths.

Board pearl: Listing "ACE inhibitor allergy" without specifying angioedema vs cough leads to inappropriate avoidance of ACEi in cough cases — specificity in documentation prevents both under- and over-flagging.

High-Yield Associations and Rapid-Fire Facts

ACEi angioedema 4–5× more common in Black patients; risk persists for years on the drug.

Median time to ACEi angioedema = months, but range is hours to >10 years.

ARB cross-reactivity with prior ACEi angioedema: ~2–10%.

Sacubitril/valsartan: contraindicated within 36 hours of ACEi and in any prior angioedema.

DPP-4 inhibitors (gliptins) + ACEi = increased angioedema risk.

tPA-induced angioedema: 1–5% of stroke patients receiving alteplase, typically contralateral to the infarct; treat as bradykinin-mediated.

HAE inheritance: autosomal dominant, 25% de novo.

HAE type I (85%): low C1-INH antigen + function; HAE type II (15%): normal/high antigen, low function.

HAE-nl-C1INH (formerly type III): normal C1-INH; F12, PLG, ANGPT1, KNG1 mutations; estrogen-sensitive, female predominant.

Acquired C1-INH deficiency: low C1q distinguishes from hereditary; associated with MGUS, B-cell lymphoma, autoimmune disease.

Erythema marginatum = non-pruritic serpiginous rash preceding HAE attack; pathognomonic.

Tryptase peaks 1–2 hours post-anaphylaxis, normalizes by 6 hours — timing matters.

Glucagon for refractory anaphylaxis in beta-blocker patients.

HAE acute therapies: C1-INH concentrate, icatibant, ecallantide; FFP as last resort.

HAE prophylaxis: SC C1-INH, lanadelumab, berotralstat; danazol second-line.

Danazol contraindications: pregnancy, children, liver disease.

Switch HAE patients to progestin-only contraception; avoid estrogen.

Biphasic anaphylaxis: 5–20%, occurs within 1–72 hours.

Two epinephrine auto-injectors at discharge — always.

Ishoo staging III–IV (tongue, larynx) = ICU + airway team.

Awake fiberoptic nasotracheal intubation preferred for angioedema airway.

Bowel wall thickening on CT in HAE looks like "stacked coins" with mesenteric edema and ascites.

Pediatric HAE often presents with abdominal attacks before laryngeal.

Board pearl: Drugs you must immediately suspect with new angioedema: ACEi, ARBs, NSAIDs, contrast agents, sacubitril/valsartan, gliptins, tPA, mTOR inhibitors. Stop the drug, document permanently.

Board Question Stem Patterns

Classic ACEi vignette: "65-year-old Black man on lisinopril for 7 years presents with isolated tongue swelling, no urticaria, no pruritus, vital signs stable, mild voice change." → Answer: stop lisinopril, admit for airway monitoring, consult ENT/anesthesia, lifelong ACEi avoidance. Distractor: "give epinephrine and diphenhydramine and discharge."

HAE vignette: "22-year-old woman with recurrent abdominal pain, vomiting, episodes of facial/extremity swelling since adolescence; father had similar episodes; today develops lip swelling 4 hours after dental procedure." → Best initial test: C4. Definitive: C1-INH level and function. Treatment: C1-INH concentrate or icatibant.

Acquired C1-INH: "58-year-old man with new-onset recurrent angioedema, low C4, low C1-INH, low C1q, no family history." → SPEP, hematology referral, search for lymphoproliferative disorder.

Sacubitril/valsartan trap: "HFrEF patient with prior ACEi angioedema, started on sacubitril/valsartan." → Recognize as contraindicated; switch to alternative.

HAE prophylaxis pre-procedure: "HAE patient needs wisdom tooth extraction." → Pre-procedural C1-INH 1 hour before procedure.

Refractory anaphylaxis on beta-blocker: "Patient with anaphylaxis not responding to 3 doses of epinephrine, on metoprolol." → Glucagon 1–5 mg IV.

Pregnant HAE patient: "30-week pregnant woman with HAE having an attack." → Plasma-derived C1-INH (Berinert).

Estrogen trigger: "Young woman with recurrent angioedema started after OCP initiation, normal C4/C1-INH." → HAE with normal C1-INH; switch to progestin-only.

tPA-induced angioedema: "Post-stroke patient on alteplase develops contralateral tongue swelling." → Stop tPA, treat as bradykinin-mediated, consider C1-INH/icatibant.

Biphasic reaction: "Patient with anaphylaxis improved after epi, observed for 1 hour, discharged, returns 8 hours later with recurrent symptoms." → Lesson: extend observation 4–6 hours minimum, longer if severe.

Ludwig angina mimic: "Fever, drooling, bilateral submandibular swelling, dental source." → Not angioedema; antibiotics + surgical drainage.

Step 3 management twist: "Patient with prior ACEi angioedema needs RAAS blockade for proteinuric CKD." → Shared decision-making, ARB with 4–6 week washout, document carefully, monitor closely; sacubitril/valsartan contraindicated.

Board pearl: When a vignette mentions "lip swelling without urticaria or pruritus," the answer is almost always bradykinin-mediated — pivot away from epinephrine-first thinking toward mechanism identification and ACEi discontinuation.

One-Line Recap

Angioedema management hinges on distinguishing histaminergic (fast, itchy, with urticaria — treat with epinephrine, antihistamines, steroids) from bradykinin-mediated (slow, non-itchy, ACEi or HAE — treat with C1-INH concentrate, icatibant, or ecallantide and stop offending drugs permanently), with airway protection as the universal first priority.

Mechanism = treatment: Histamine pathway responds to epinephrine + antihistamines + steroids; bradykinin pathway responds only to C1-INH, icatibant, or ecallantide — misclassification costs lives but empiric dual therapy is reasonable when uncertain.

Airway first, always: Tongue protrusion, stridor, voice change, drooling → ICU, awake fiberoptic intubation by most experienced operator, surgical airway backup ready. Ishoo stages III–IV mandate immediate airway team mobilization.

Lab triage for bradykinin angioedema: C4 is the screening test → if low, order C1-INH level and function and C1q (low C1q = acquired, normal C1q = hereditary). Tryptase (1–2 hr peak) supports mast cell activation.

Lifelong avoidance is non-negotiable: ACEi-induced angioedema = permanent ACEi avoidance, sacubitril/valsartan contraindicated, ARB only after careful shared decision-making. Document mechanism in EHR allergy field, notify pharmacy and outpatient providers, and provide a written action plan with two epinephrine auto-injectors at discharge for histaminergic cases.

Board pearl: The single most tested concept is recognizing isolated, non-pruritic, non-urticarial tongue/lip swelling in a patient on an ACE inhibitor as bradykinin-mediated angioedema — stop the drug, protect the airway, document the allergy, and consider targeted bradykinin therapy for moderate-to-severe attacks. Never re-challenge.